-

VALERIO THERAPEUTICS: List of the Board Members Positions Held in Other Companies as of March 19, 2025

PARIS--(BUSINESS WIRE)--Regulatory News:

VALERIO THERAPEUTICS (Paris:ALVIO):

 Name of Director

Other offices and functions

 

Julien MIARA

Chief Executive Officer and Director

 

  • Managing Director at Invus
  • Director of Sensorion
  • Director of Versity

 

Jacques MALLET

Director and Chairman of the Board

 

  • Chairman of Gamma-X Corporate Advisory
  • Director of Technoflex
  • Director of the Fournier Majoie Foundation

 

FINANCIERE DE LA MONTAGNE, represented by Nicolas TREBOUTA

Director

 

  • Manager of SARL Financière de la Montagne
  • Manager of SCI Fleurus Immobilier
  • Chairman of SAS Dragon 8
  • Managing partner of SC Financière des Associés
  • Chairman of the Supervisory Board of SCA Chevrillon & Associés
  • Manager of EARL Ferme de Bissy
  • Managing partner of SC Valois
  • Co-manager of SC Aster
  • Managing partner of SCI du Chardonnet

 

Bryan GIRAUDO

Director

 

  • Chief Operating Officer and Chief Financial Officer of Gossamer Bio Inc
  • Director of Protagonist Therapeutics
  • Senior Managing Director at Leerink Partners

Antoine BAROUKY

Chief Operating Officer and Director

  • Chairman & CEO of MAAsiRNA
  • Chairman & CEO of AB Global Strategy
  • Venture Partner at Invus

 

Shefali AGARWAL

Director

 

  • Member of the Board of Directors of ITB Med (unlisted)
  • Member of the Board of Directors of Gritstone Bio (Nasdaq: GTRS)
  • Member of the Board of Directors of Fate Therapeutics (Nasdaq: FATE)

VALERIO THERAPEUTICS
Société anonyme à conseil d’administration au capital social de 21.610.998,20 euros
Siège social : 49 boulevard du Général Martial Valin, 75015 Paris 410 910 095 R.C.S. Paris

Contacts

VALERIO THERAPEUTICS

VALERIO THERAPEUTICS

BOURSE:ALVIO

Release Versions

Contacts

VALERIO THERAPEUTICS

More News From VALERIO THERAPEUTICS

Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the completion of the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). Further to the closing of the cash consideration of the Acquisition which occurred in August1, the Company has now proceeded to...

Valerio Therapeutics Provides an Update on Its Business and Presents Its Financial Results for the First Half of 2026

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a pioneering biotechnology company in the field of next-generation precision therapies (“Valerio”, or the “Company”), provides an update on its operations and presents its financial results for the half-year ended 30 June 2026. “The first half of 2026 marked a decisive milestone in the consolidation of our strategic refocusing and in the transformation of Valerio Therapeutics. The operational launc...

Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors 

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the signing of a definitive share purchase agreement (the "SPA") and of the related contribution agreement (the "Contribution Agreement") for the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"), ba...
Back to Newsroom